CTRVP
Hepion Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.00
+0.00 (+0.00%)
Current Price
| Previous Close | $0.00 |
| Open | $0.00 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 10 |
Stock Information
| Cash Equivalents | $2.60M |
| Net Income | $-2.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| EPS (TTM) | $-1.41 |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-870K |
| Income | $-2.98M |
| Book/sh | $0.01 |
| Employees | 2 |
Financial Ratios
| Quick Ratio | 3.54 |
| Current Ratio | 3.68 |
Returns & Margins
| ROA | -45.42% |
| ROE | -103.70% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.09 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.00 |
| SMA50 | $0.00 |
| SMA200 | $0.00 |
| RSI | nan |
| Shares Float | 21.62M |
| Volatility | 1.66 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| 6 Months | +0.00% |
| YTD | +0.00% |
| 10 Years | +0.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $0.00 | 0 |
| 2026-06-16 | $0.00 | 0 |
| 2026-06-15 | $0.00 | 0 |
| 2026-06-12 | $0.00 | 0 |
| 2026-06-11 | $0.00 | 0 |
| 2026-06-10 | $0.00 | 0 |
| 2026-06-09 | $0.00 | 0 |
| 2026-06-08 | $0.00 | 0 |
| 2026-06-05 | $0.00 | 0 |
| 2026-06-04 | $0.00 | 0 |
| 2026-06-03 | $0.00 | 0 |
| 2026-06-02 | $0.00 | 0 |
| 2026-06-01 | $0.00 | 0 |
| 2026-05-29 | $0.00 | 0 |
| 2026-05-28 | $0.00 | 0 |
| 2026-05-27 | $0.00 | 0 |
| 2026-05-26 | $0.00 | 0 |
| 2026-05-22 | $0.00 | 0 |
| 2026-05-21 | $0.00 | 0 |
| 2026-05-20 | $0.00 | 0 |
| 2026-05-19 | $0.00 | 0 |
| 2026-05-18 | $0.00 | 0 |
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
đ° Latest News
No news articles available at the moment. Check back later for updates on CTRVP.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $1,247,313 | $9,465 | $10,164 | $8,859 |
| Total Expenses | $19,346,578 | $45,257,954 | $43,617,802 | $30,403,309 |
| Other Income Expense | $4,432,219 | $-4,067,645 | $-1,455,932 | $-2,310,000 |
| Net Non Operating Interest Income Expense | $-1,247,313 | $-9,465 | $-10,164 | $-8,859 |
| Interest Expense Non Operating | $1,247,313 | $9,465 | $10,164 | $8,859 |
| Operating Expense | $19,346,578 | $45,257,954 | $43,617,802 | $30,403,309 |
| General And Administrative Expense | $7,499,230 | $9,618,298 | $10,348,465 | $10,008,173 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-13,192,420 | $-48,926,042 | $-42,200,049 | $-32,722,168 |
| Net Interest Income | $-1,247,313 | $-9,465 | $-10,164 | $-8,859 |
| Normalized Income | $-16,809,111 | $-44,890,938 | $-40,837,297 | $-30,412,168 |
| Net Income From Continuing And Discontinued Operation | $-13,192,420 | $-48,926,042 | $-42,200,049 | $-32,722,168 |
| Total Operating Income As Reported | $-19,346,578 | $-48,447,954 | $-45,488,726 | $-30,403,309 |
| Net Income Common Stockholders | $-13,192,420 | $-48,926,042 | $-45,337,549 | $-32,722,168 |
| Net Income | $-13,192,420 | $-48,926,042 | $-42,200,049 | $-32,722,168 |
| Net Income Including Noncontrolling Interests | $-13,192,420 | $-48,926,042 | $-42,200,049 | $-32,722,168 |
| Net Income Continuous Operations | $-13,192,420 | $-48,926,042 | $-42,200,049 | $-32,722,168 |
| Pretax Income | $-16,161,672 | $-49,335,064 | $-45,083,898 | $-32,722,168 |
| Special Income Charges | $-3,167,044 | $-3,190,000 | $-1,870,924 | $0 |
| Operating Income | $-19,346,578 | $-45,257,954 | $-43,617,802 | $-30,403,309 |
| Other | ||||
| Tax Effect Of Unusual Items | $815,528 | $-32,541 | $-93,180 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-19,315,820 | $-45,190,823 | $-43,540,341 | $-30,317,236 |
| Total Unusual Items | $4,432,219 | $-4,067,645 | $-1,455,932 | $-2,310,000 |
| Total Unusual Items Excluding Goodwill | $4,432,219 | $-4,067,645 | $-1,455,932 | $-2,310,000 |
| Reconciled Depreciation | $30,758 | $67,131 | $77,461 | $86,073 |
| EBITDA (Bullshit earnings) | $-14,883,601 | $-49,258,468 | $-44,996,273 | $-32,627,236 |
| EBIT | $-14,914,359 | $-49,325,599 | $-45,073,734 | $-32,713,309 |
| Diluted NI Availto Com Stockholders | $-13,192,420 | $-48,926,042 | $-45,337,549 | $-32,722,168 |
| Tax Provision | $-2,969,252 | $-409,022 | $-2,883,849 | $0 |
| Other Special Charges | $2,567,044 | - | - | - |
| Write Off | $600,000 | $0 | - | - |
| Impairment Of Capital Assets | $0 | $3,190,000 | $1,870,924 | $0 |
| Gain On Sale Of Security | $7,599,263 | $-877,645 | $414,992 | $-2,310,000 |
| Research And Development | $11,847,348 | $35,639,656 | $33,269,337 | $20,395,136 |
| Selling General And Administration | $7,499,230 | $9,618,298 | $10,348,465 | $10,008,173 |
| Other Gand A | $7,499,230 | $9,618,298 | $10,348,465 | $10,008,173 |
| Otherunder Preferred Stock Dividend | - | $0 | $3,137,500 | $0 |
| Preferred Stock Dividends | - | - | $3,137,500 | - |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,863,338 | $7,280,807 | $49,855,937 | $91,124,079 |
| Total Assets | $1,613,737 | $18,094,397 | $60,244,452 | $103,552,479 |
| Total Non Current Assets | $-1 | $606,557 | $3,748,379 | $6,100,711 |
| Current Assets | $1,613,737 | $17,487,840 | $56,496,073 | $97,451,768 |
| Prepaid Assets | $1,207,329 | $2,701,960 | $5,306,985 | $6,102,801 |
| Cash Cash Equivalents And Short Term Investments | $406,408 | $14,785,880 | $51,189,088 | $91,348,967 |
| Cash And Cash Equivalents | $406,408 | $14,785,880 | $51,189,088 | $91,348,967 |
| Cash Financial | $406,408 | $14,785,880 | $51,189,088 | $91,348,967 |
| Other Non Current Assets | - | $364,192 | $426,174 | $583,326 |
| Goodwill And Other Intangible Assets | - | $0 | $3,190,000 | $1,870,924 |
| Other Intangible Assets | - | - | $3,190,000 | $3,190,000 |
| Debt | ||||
| Net Debt | $2,493,592 | - | - | - |
| Total Debt | $2,900,000 | $209,020 | $53,614 | $316,992 |
| Long Term Debt And Capital Lease Obligation | $0 | $93,104 | $0 | $50,342 |
| Current Debt And Capital Lease Obligation | $2,900,000 | $115,916 | $53,614 | $266,650 |
| Current Debt | $2,900,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,477,075 | $10,813,590 | $10,388,515 | $10,557,476 |
| Total Non Current Liabilities Net Minority Interest | $333,189 | $5,523,494 | $2,502,793 | $2,351,080 |
| Derivative Product Liabilities | $333,189 | $3,796,390 | $0 | $0 |
| Current Liabilities | $3,143,886 | $5,290,096 | $7,885,722 | $8,206,396 |
| Current Notes Payable | $2,900,000 | $0 | - | - |
| Payables And Accrued Expenses | $243,886 | $4,788,180 | $5,559,478 | $3,314,154 |
| Payables | $220,202 | $2,348,829 | $2,665,896 | $2,445,837 |
| Accounts Payable | $220,202 | $2,348,829 | $2,665,896 | $2,445,837 |
| Other Non Current Liabilities | - | $1,634,000 | $2,093,771 | $1,891,716 |
| Non Current Deferred Liabilities | - | $0 | $409,022 | $409,022 |
| Non Current Deferred Taxes Liabilities | - | $0 | $409,022 | $409,022 |
| Other Current Liabilities | - | $386,000 | $366,229 | $2,988,284 |
| Total Tax Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $-3,558,466 | $5,585,679 | $48,159,809 | $91,293,875 |
| Preferred Stock Equity | $1,695,128 | $1,695,128 | $1,696,128 | $1,701,128 |
| Total Equity Gross Minority Interest | $-1,863,338 | $7,280,807 | $49,855,937 | $92,995,003 |
| Stockholders Equity | $-1,863,338 | $7,280,807 | $49,855,937 | $92,995,003 |
| Gains Losses Not Affecting Retained Earnings | $8,345 | $-78,779 | $-90,168 | $0 |
| Other Equity Adjustments | $8,345 | $-78,779 | $-90,168 | - |
| Retained Earnings | $-237,819,806 | $-224,627,386 | $-175,701,344 | $-133,501,295 |
| Other | ||||
| Preferred Shares Number | $87,269 | $87,269 | $87,382 | $1,806 |
| Ordinary Shares Number | $139,168 | $96,374 | $76,229 | $76,225 |
| Share Issued | $139,168 | $96,374 | $76,229 | $76,225 |
| Tangible Book Value | $-3,558,466 | $5,585,679 | $48,159,809 | $89,422,951 |
| Invested Capital | $-658,466 | $5,585,679 | $48,159,809 | $91,293,875 |
| Working Capital | $-1,530,149 | $12,197,744 | $48,610,351 | $89,245,372 |
| Capital Lease Obligations | $0 | $209,020 | $53,614 | $316,992 |
| Total Capitalization | $-1,863,338 | $7,280,807 | $49,855,937 | $92,995,003 |
| Additional Paid In Capital | $234,252,981 | $230,291,834 | $223,950,940 | $224,787,547 |
| Capital Stock | $1,695,142 | $1,695,138 | $1,696,509 | $1,708,751 |
| Common Stock | $14 | $10 | $381 | $7,623 |
| Preferred Stock | $1,695,128 | $1,695,128 | $1,696,128 | $1,701,128 |
| Long Term Capital Lease Obligation | $0 | $93,104 | $0 | $50,342 |
| Current Capital Lease Obligation | $0 | $115,916 | $53,614 | $266,650 |
| Current Accrued Expenses | $23,684 | $2,439,351 | $2,893,582 | $868,317 |
| Net PPE | $-1 | $242,365 | $3,322,205 | $3,646,461 |
| Accumulated Depreciation | $-420,732 | $-379,466 | $-306,945 | $-240,241 |
| Gross PPE | $420,731 | $621,831 | $3,629,150 | $3,886,702 |
| Other Properties | $358,548 | $559,648 | $326,382 | $330,830 |
| Machinery Furniture Equipment | $62,183 | $62,183 | $62,183 | $62,183 |
| Pensionand Other Post Retirement Benefit Plans Current | - | $0 | $1,906,401 | $1,637,308 |
| Buildings And Improvements | - | $212,878 | $3,240,585 | $3,493,689 |
| Properties | - | $0 | $0 | $0 |
| Goodwill | - | - | $0 | $1,870,924 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-18,216,303 | $-40,903,182 | $-34,977,507 | $-31,354,886 |
| Operating Activities | ||||
| Operating Cash Flow | $-18,216,303 | $-40,888,878 | $-34,961,171 | $-31,224,481 |
| Cash Flow From Continuing Operating Activities | $-18,216,303 | $-40,888,878 | $-34,961,171 | $-31,224,481 |
| Operating Gains Losses | $-5,579,263 | $1,317,646 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $-600,000 | $-14,304 | $-14,070 | $-130,405 |
| Cash Flow From Continuing Investing Activities | $-600,000 | $-14,304 | $-14,070 | $-130,405 |
| Net Other Investing Changes | $-600,000 | - | - | - |
| Capital Expenditure | - | $-14,304 | $-16,336 | $-130,405 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $2,500,000 | $0 | $17,862,500 | $82,153,600 |
| Financing Cash Flow | $4,349,707 | $4,494,950 | $-5,137,500 | $81,977,015 |
| Cash Flow From Continuing Financing Activities | $4,349,707 | $4,494,950 | $-5,137,500 | $81,977,015 |
| Net Common Stock Issuance | $2,500,000 | $0 | $0 | $82,153,600 |
| Common Stock Issuance | $2,500,000 | $0 | $0 | $82,153,600 |
| Repurchase Of Capital Stock | - | $0 | $-21,000,000 | $0 |
| Net Preferred Stock Issuance | - | $0 | $-3,137,500 | $0 |
| Preferred Stock Issuance | - | $0 | $17,862,500 | $0 |
| Net Other Financing Charges | - | - | $-2,000,000 | - |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $941 | $2,024 |
| End Cash Position | $406,408 | $14,785,880 | $51,189,088 | $91,348,967 |
| Beginning Cash Position | $14,785,880 | $51,189,088 | $91,348,967 | $40,726,838 |
| Effect Of Exchange Rate Changes | $87,124 | $5,024 | $-47,138 | $0 |
| Changes In Cash | $-14,466,596 | $-36,408,232 | $-40,112,741 | $50,622,129 |
| Proceeds From Stock Option Exercised | $1,849,707 | $4,494,950 | $0 | $0 |
| Net PPE Purchase And Sale | $0 | $-14,304 | $-14,070 | $-130,405 |
| Purchase Of PPE | $0 | $-14,304 | $-16,336 | $-130,405 |
| Change In Working Capital | $-2,682,884 | $2,971,098 | $3,152,749 | $-5,567,201 |
| Change In Other Current Liabilities | $-209,020 | $-96,712 | $-263,378 | $-258,589 |
| Change In Other Current Assets | $212,878 | $89,825 | $253,104 | $252,803 |
| Change In Payables And Accrued Expense | $-4,545,565 | $302,919 | $2,245,715 | $-1,067,847 |
| Change In Prepaid Assets | $1,858,823 | $2,675,066 | $917,308 | $-4,493,568 |
| Other Non Cash Items | $1,815,861 | $-440,000 | $-414,992 | $2,310,000 |
| Stock Based Compensation | $791,645 | $1,340,311 | $2,552,736 | $4,668,815 |
| Asset Impairment Charge | $600,000 | $3,190,000 | $1,870,924 | $0 |
| Deferred Tax | $0 | $-409,022 | $0 | - |
| Deferred Income Tax | $0 | $-409,022 | $0 | - |
| Depreciation Amortization Depletion | $30,758 | $67,131 | $77,461 | $86,073 |
| Depreciation And Amortization | $30,758 | $67,131 | $77,461 | $86,073 |
| Depreciation | $30,758 | $67,131 | - | - |
| Gain Loss On Investment Securities | $-5,579,263 | $1,317,646 | - | - |
| Net Income From Continuing Operations | $-13,192,420 | $-48,926,042 | $-42,200,049 | $-32,722,168 |
| Preferred Stock Payments | - | $0 | $-21,000,000 | $0 |
| Sale Of PPE | - | $0 | $2,266 | $0 |
| Repayment Of Debt | - | - | $0 | $-176,585 |
| Net Issuance Payments Of Debt | - | - | $0 | $-176,585 |
| Net Long Term Debt Issuance | - | - | $0 | $-176,585 |
| Long Term Debt Payments | - | - | $0 | $-176,585 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | $252,803 |
Fetched: 2026-02-02